Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Filling in the Evidence About Sunscreen

Filling in the Evidence About Sunscreen Opinion EDITORIAL Robert M. Califf, MD; Kanade Shinkai, MD, PhD Skin cancer is the most common malignancy in the United through day 7 for all products except the cream. The concen- States and is estimated to affect more than 3.3 million indi- tration increased from day 1 to day 4, raising the suggestion viduals each year. Photoprotection, including sunscreen use of drug accumulation. Application of products with oxyben- zone and octocrylene resulted in similar exposures, with for areas of skin not covered by sun protective clothing or shade, aims to reduce exposure to UV radiation, likely concentrations exceeding 0.5 ng/mL, demonstrating rising the main risk factor for the development of skin cancer. plasma concentrations with ongoing use—consistent with Sunscreens were initially approved as over-the-counter drug accumulation—as well as persistent systemic levels (OTC) medications—indicated for the prevention of sunburn— after discontinuing the sunscreen use, suggesting an before the modern era of drug evaluation. Current understand- extended half-life. Among the 6 participants using the cream ing of UV-related carcinogenesis supports the additional in- (the only product with ecamsule), 5 had ecamsule concen- dication regarding use of trations exceeding 0.5 ng/mL on day 1. Notably, post hoc sunscreen for the prevention analysis http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Filling in the Evidence About Sunscreen

JAMA , Volume 321 (21) – Jun 4, 2019

Loading next page...
 
/lp/american-medical-association/filling-in-the-evidence-about-sunscreen-EufZGWrjs0
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.5528
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Robert M. Califf, MD; Kanade Shinkai, MD, PhD Skin cancer is the most common malignancy in the United through day 7 for all products except the cream. The concen- States and is estimated to affect more than 3.3 million indi- tration increased from day 1 to day 4, raising the suggestion viduals each year. Photoprotection, including sunscreen use of drug accumulation. Application of products with oxyben- zone and octocrylene resulted in similar exposures, with for areas of skin not covered by sun protective clothing or shade, aims to reduce exposure to UV radiation, likely concentrations exceeding 0.5 ng/mL, demonstrating rising the main risk factor for the development of skin cancer. plasma concentrations with ongoing use—consistent with Sunscreens were initially approved as over-the-counter drug accumulation—as well as persistent systemic levels (OTC) medications—indicated for the prevention of sunburn— after discontinuing the sunscreen use, suggesting an before the modern era of drug evaluation. Current understand- extended half-life. Among the 6 participants using the cream ing of UV-related carcinogenesis supports the additional in- (the only product with ecamsule), 5 had ecamsule concen- dication regarding use of trations exceeding 0.5 ng/mL on day 1. Notably, post hoc sunscreen for the prevention analysis

Journal

JAMAAmerican Medical Association

Published: Jun 4, 2019

References